BioStem Showcases Its Leading BioREtain® Allograft Technology at SAWC Fall Meeting
Summary: BioStem Technologies, Inc. (OTC: BSEM), a med-tech company focused on placental-derived products for advanced wound care, is presenting its allograft portfolio at the Symposium for Advanced Wound Care (SAWC) Fall Meeting in Las Vegas, Sept 3-6, alongside its commercial partner Venture Medical, LLC. The company is spotlighting scientific poster presentations, its BioREtain® processing platform, and the Venture OneView™ logistics platform to streamline delivery of skin substitute treatments for chronic wounds.
Key Highlights:
- BioStem will co-exhibit with Venture Medical, LLC, to demonstrate how its placental allograft products—**AmnioWrap2®** and **Vendaje AC®**—integrate with the Venture OneView™ platform, enhancing efficiencies in patient care logistics and skin substitute management.
- The BioStem-Venture exhibit includes scheduled sessions such as *Debunking Wound Care Myths* and *Do’s & Don’ts of Mobile Wound Care*, providing attendees opportunities to explore both clinical and operational insights in wound care delivery.
- A special breakfast symposium titled *Navigating the Future of Wound Care*, moderated by Michael Desvigne, MD, will focus on real-world clinical evidence, selecting appropriate allografts, optimizing practice flow, and performing mobile wound care practice successfully.
- Three posters have been accepted for display in the poster hall:
• *A Simple Comparison of Real-World Pressure Ulcer Data*
• *A Direct Comparison of Processing Methods for Placental Tissue Allografts*
• *A Comparison of Sterilization Methods for Dehydrated Birth Tissue* - BioStem emphasizes that its BioREtain® processing method—through a proprietary six-step process—preserves the tissue matrix and structure typical of fresh perinatal tissue, including growth factors and integrity, which the company claims supports superior clinical outcomes in chronic wound care.
- The placental allografts are manufactured in an FDA-registered, AATB-accredited facility in Pompano Beach, Florida, under rigorous quality practices (cGTP and cGMP) to ensure both safety and potency.
Read the full press release via BioStem / GlobeNewswire
Keywords:
BioREtain technology,
placental allografts,
AmnioWrap2,
Vendaje AC,
OneView platform,
Venture Medical,
BioStem Technologies